Download PDF
Klin Padiatr 2013; 225(S 01): S79-S86
DOI: 10.1055/s-0033-1337968
Zum 80. Geburtstag von Prof. Riehm
© Georg Thieme Verlag KG Stuttgart · New York

Development of a Curative Treatment within the AML-BFM Studies[*]

Entwicklung einer kurativen Therapie im Rahmen der AML-BFM-Studien
U. Creutzig
1   Paediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany
,
M. Zimmermann
1   Paediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany
,
M. N. Dworzak
2   Department of Paediatrics Medical University of Vienna, St. Anna Children’s Hospital and Children’s Cancer Research ­Institute, Vienna, Austria
,
J. Ritter
3   Deparment of Paediatric Haematology and Oncology, University Children’s Hospital, Münster, Germany
,
G. Schellong
3   Deparment of Paediatric Haematology and Oncology, University Children’s Hospital, Münster, Germany
,
D. Reinhardt
1   Paediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
22 May 2013 (online)

Also available at
    Permissions and Reprints

Abstract

The first multicenter treatment study for AML in childhood in Germany was performed from 1978 onwards. The therapy plan was designed similar to that for the acute lymphoblastic leukaemia (ALL). The drugs with the highest efficacy in AML, cytarabine cutting catara-bine and anthracyclines, were combined during induction and consolidation, followed by preventive cranial irradiation and maintenance therapy similar to that in ALL. The remission rate of the initial study was 80%, and the 5-year survival rate increased from less than 10% before 1970 to 40%. 5 subsequent trials have further increased the 5-year survival to now 70% and even 90% in the subgroup of core-binding factor leukaemias by using an intensified and optimised treatment schedule.

The AML-BFM studies were the only prospective study sequence testing the benefit of cranial irradiation. Results from study -87 including the non-randomized patients showed an increased risk of CNS and/or bone marrow relapses in non-irradiated patients. Later on there was evidence that 12 Gy resulted in the same relapse rate as 18 Gy. The AML-BFM studies always used the experience from the previous study to optimize the next study. This approach was essential together with improved supportive treatment and experience of the medical staff for the step-wise and considerable increase of longterm survival within the 6 subsequent AML-BFM studies.

Zusammenfassung

Die erste multizentrische Therapiestudie bei Kindern mit AML in Deutschland wurde 1978 unter der ­Leitung von G. Schellong begonnen. Die Therapiestrategie war anfangs ähnlich aufgebaut wie die der akuten lympho­blastischen Leukämie (ALL), wobei die bei der AML verstärkt wirksamen Substanzen Cytarabin und Anthrazykline in den Induktions- und Konsolidierungsphasen stärker gewichtet wurden. Eine präventive Schädelbestrahlung und eine Erhaltungstherapie wurden ebenfalls nach dem Muster der ­ALL-Therapie gegeben. Fast 80% der Patienten erreichten eine Remission, und die 5-Jahres-Überlebensrate konnte von unter 10% vor 1970 auf 40% angehoben werden. In den weiteren Studien wurde die Therapie deutlich in­tensiviert und optimiert, so dass heute eine 5-Jahresüberlebensrate von 70% möglich ist. Sie liegt sogar bei 90% in der Gruppe der „Core-Bin­ding“ Faktor Leukämien.

Die AML-BFM Studiengruppe ist die einzige, die die Wirksamkeit der Schädelbestrahlung geprüft hat. Ergebnisse der Studie -87 zeigten unter Einschluss der nicht-randomisierten Patienten ein erhöhtes Risiko für Rezidive im Zentralnervensystem (ZNS) und/oder Knochenmark bei nicht bestrahlten Patienten. Später konnte gezeigt werden, dass die Ergebnisse mit 12 Gy oder 18 Gy gleich sind. In den AML-BFM-Studien wurden jeweils die Erfahrungen der Vorgängerstudie zur Optimierung der folgenden Studie genutzt. Dieses Vorgehen hat ganz entscheidend, zusammen mit der Verbesserung der supportiven The­rapie und dem Erfahrungsgewinn der Teilnehmer, zu dem beträchtlichen Anstieg der Langzeitüberlebensraten im Rahmen der sechs aufeinanderfolgenden AML-BFM Therapiestudien geführt.

Key words

acute myeloid leukaemia - children - AML-BFM studies - diagnosis - treatment

Schlüsselwörter

akute myeloische Leukämie - Kinder - AML-BFM Studien - Diagnose - Behandlung
*

* supported by the Deutsche Krebshilfe e.V.


 

  • References

  • 1 Vereinbarung des Gemeinsamen Bundesausschusses über Maßnahmen zur Qualitätssicherung für die stationäre Versorgung von Kindern und Jugendlichen mit hämato-onkologischen Krankheiten gemäß § 137 Abs. 1 Satz 3 Nr. 2 SGB V für nach § 108 SGB V zugelassene Krankenhäuser (Vereinbarung zur Kinderonkologie). http://www.g-ba.de/informationen/beschluesse/290/2006
    PubMed
  • 2 Abrahamsson J, Forestier E, Heldrup J et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011; 29: 310-315
    CrossrefPubMedGoogle Scholar
  • 3 Bene MC, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783-1786
    PubMedGoogle Scholar
  • 4 Bennett JM, Catovsky D, Daniel MT et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985; 103: 626-629
    CrossrefPubMedGoogle Scholar
  • 5 Bennett JM, Catovsky D, Daniel MT et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991; 78: 325-329
    CrossrefPubMedGoogle Scholar
  • 6 Bielack SS, Erttmann R, Kempf Bielack B et al. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?. Eur J Cancer 1996; 32A: 1652-1660
    PubMedGoogle Scholar
  • 7 Burnett AK, Hills RK, Milligan DW et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010; 28: 586-595
    CrossrefPubMedGoogle Scholar
  • 8 Corrigan JJ, Feig SA. Guidelines for pediatric cancer centers. Pediatrics 2004; 113: 1833-1835
    CrossrefPubMedGoogle Scholar
  • 9 Creutzig U. Kommentar: Krebs bei Kindern und Jugendlichen – Versorgung in Zentren. Dtsch Arztebl 2012; 109 A-18/B-15/C-15-
    PubMedGoogle Scholar
  • 10 Creutzig U, Reinhardt D. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation? – A European view. Br J Haematol 2002; 118: 365-377
    CrossrefPubMedGoogle Scholar
  • 11 Creutzig U, Reinhardt D, Diekamp S et al. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 2005; 19: 1355-1360
    CrossrefPubMedGoogle Scholar
  • 12 Creutzig U, Reinhardt D, Zimmermann M et al. Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies. Blood 2001; 97: 3671-3672
    CrossrefPubMedGoogle Scholar
  • 13 Creutzig U, Ritter J, Budde M et al. Aktuelle Ergebnisse der kooperativen AMLTherapiestudien bei Kindern: BFM-78 und -83. Klin Pädiatr 1986; 198: 183-190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Creutzig U, Ritter J, Budde M et al. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987; 60: 3071-3079
    CrossrefPubMedGoogle Scholar
  • 15 Creutzig U, Ritter J, Niederbierbaum-Koczy G et al. Prognostische Bedeutung der Eosinophilie bei Kindern mit akuter myeloischer Leukämie in den Studien AMLBFM- 78 und -83. Klin Pädiatr 1989; 201: 220-226
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Creutzig U, Ritter J, Riehm H et al. The childhood AML-studies BFM-78 and -83: Treatment results and risk factor analysis. Haematol Blood Transf 1987; 30: 71-75
    PubMedGoogle Scholar
  • 17 Creutzig U, Ritter J, Riehm H et al. Improved treatment results in childhood acute myelogenous leukemia: A report of the German cooperative study AML-BFM-78. Blood 1985; 65: 298-304
    PubMedGoogle Scholar
  • 18 Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 1990; 75: 1932-1940
    PubMedGoogle Scholar
  • 19 Creutzig U, Ritter J, Zimmermann M et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: Results of study AML-BFM 93. Leukemia 2001; 15: 348-354
    PubMedGoogle Scholar
  • 20 Creutzig U, Ritter J, Zimmermann M et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt- Münster 93. J Clin Oncol 2001; 19: 2705-2713
    PubMedGoogle Scholar
  • 21 Creutzig U, Ritter J, Zimmermann M et al. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia (AML): unexpected results of the childhood AML Study BFM-87. J Clin Oncol 1993; 11: 279-286
    PubMedGoogle Scholar
  • 22 Creutzig U, Ch Sperling, Harbott J et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of Study AML-BFM-87. Blood 1995; 86: 3097-3108
    PubMedGoogle Scholar
  • 23 Creutzig U, Van den Heuvel-Eibrink MM, Gibson B et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel, on behalf of the AML Committee of the International BFM Study Group. Blood 2012; 120: 3187-3205
    CrossrefPubMedGoogle Scholar
  • 24 Creutzig U, Zimmermann M, Bourquin JP et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AML-BFM98 and 2004. Pediatr Blood Cancer 2011; 57: 986-992
    CrossrefPubMedGoogle Scholar
  • 25 Creutzig U, Zimmermann M, Bourquin JP et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood 2011; 118: 5409-5415
    CrossrefPubMedGoogle Scholar
  • 26 Creutzig U, Zimmermann M, Dworzak M et al. Randomized introduction of liposomal daunorubicin (L-DNR) in a higher equivalent dose than idarubicin during induction: Improved Results in Study AML-BFM 2004. Blood 2010; 116: 83-83
    PubMedGoogle Scholar
  • 27 Creutzig U, Zimmermann M, Dworzak M et al. Study AML-BFM 2004: Improved Survival In Childhood Acute Myeloid Leukemia without Increased Toxicity. Blood 2010; 116: 83-83
    PubMedGoogle Scholar
  • 28 Creutzig U, Zimmermann M, Dworzak M et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol 2010; 149: 399-409
    CrossrefPubMedGoogle Scholar
  • 29 Creutzig U, Zimmermann M, Hannemann J et al. Quality management within the competence network of paediatric oncology and haematology. Klin Padiatr 2003; 215: 338-340
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Creutzig U, Zimmermann M, Lehrnbecher T et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499-4506
    CrossrefPubMedGoogle Scholar
  • 31 Creutzig U, Zimmermann M, Reinhardt D et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384-4393
    CrossrefPubMedGoogle Scholar
  • 32 Creutzig U, Zimmermann M, Ritter J et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999; 104: 630-639
    CrossrefPubMedGoogle Scholar
  • 33 Creutzig U, Zimmermann M, Ritter J et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030-2042
    CrossrefPubMedGoogle Scholar
  • 34 Diekamp S, Creutzig U, Reinhardt D et al. Transitorisch myeloproliferatives Syndrom bei Neugeborenen mit Down Syndrom: Überblick und Analyse von 115 Patienten aus den AML-BFM Studien und der ESPED-Studie. Monatsschrift Kinderheilkunde 2006; 154: 162-168
    CrossrefPubMedGoogle Scholar
  • 35 Dohner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453-474
    CrossrefPubMedGoogle Scholar
  • 36 Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10: 293-310
    CrossrefPubMedGoogle Scholar
  • 37 Ehlers S, Herbst C, Zimmermann M et al. Granulocyte colony-stimulating factor (GCSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 2010; 28: 2591-2597
    CrossrefPubMedGoogle Scholar
  • 38 Fernandez HF, Sun Z, Yao X et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361: 1249-1259
    CrossrefPubMedGoogle Scholar
  • 39 Franklin J, Alonzo T, Hurwitz CA et al. COG AAML03P1: Efficacy and Safety in a Pilot Study of Intensive Chemotherapy Including Gemtuzumab in Children Newly Diagnosed with Acute Myeloid Leukemia (AML). Blood 2008; 112: 56-56
    CrossrefPubMedGoogle Scholar
  • 40 Gibson BE, Webb DK, Howman AJ et al. Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial. British Journal of Haematology 2011; 155: 366-376
    CrossrefPubMedGoogle Scholar
  • 41 Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849
    PubMedGoogle Scholar
  • 42 Hasle H. Pattern of malignant disorders in individuals with Down’s syndrome. Lancet Oncol 2001; 2: 429-436
    CrossrefPubMedGoogle Scholar
  • 43 Hitzler JK, Cheung J, Li Y et al. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 2003; 101: 4301-4304
    CrossrefPubMedGoogle Scholar
  • 44 Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-572
    PubMedGoogle Scholar
  • 45 Inaba H, Rubnitz JE, Coustan-Smith E et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol 2011; 29: 3293-3300
    CrossrefPubMedGoogle Scholar
  • 46 Jabbour E, Kantarjian H, Cortes J. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action. Leuk Lymphoma 2004; 45: 2187-2195
    CrossrefPubMedGoogle Scholar
  • 47 Kallage V, Muller JE, Zimmermann M et al. Prognosis, treatment completion, and complications in nonresponders in the study AML-BFM87. Klin Padiatr 1999; 211: 250-259
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Klusmann JH, Creutzig U, Zimmermann M et al. Treatment and prognostic impact of transient leukemia in neonates with Down’s syndrome. Blood 2008; 111: 2991-2998
    CrossrefPubMedGoogle Scholar
  • 49 Klusmann JH, Reinhardt D, Zimmermann M et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2012; 97: 21-29
    CrossrefPubMedGoogle Scholar
  • 50 Lehrnbecher T, Varwig D, Kaiser J et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AMLBFM 93. Leukemia 2004; 18: 72-77
    CrossrefPubMedGoogle Scholar
  • 51 Lie SO, Abrahamsson J, Clausen N et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down’s syndrome: results of NOPHO-AML trials. Br J Haematol 2003; 122: 217-225
    CrossrefPubMedGoogle Scholar
  • 52 Lie SO, Abrahamsson J, Clausen N et al. Long-term results in children with AML: NOPHO-AML Study Group–report of three consecutive trials. Leukemia 2005; 19: 2090-2100
    PubMedGoogle Scholar
  • 53 Mann G, Reinhardt D, Ritter J et al. Treatment with all-trans retinoid acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001; 80: 417-422
    CrossrefPubMedGoogle Scholar
  • 54 Niewerth D, Creutzig U, Bierings MB et al. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010; 116: 2205-2214
    CrossrefPubMedGoogle Scholar
  • 55 Pession A, Rondelli R, Basso G et al. Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 2005; 19: 2043-2053
    PubMedGoogle Scholar
  • 56 Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 257-268
    CrossrefPubMedGoogle Scholar
  • 57 Reinhardt D, Diekamp S, Fleischhack G et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie 2004; 27: 269-272
    CrossrefPubMedGoogle Scholar
  • 58 Reinhardt D, von Neuhoff C, Sander A et al. Genetic Prognostic Factors in Childhood Acute Myeloid Leukemia. Klin Padiatr 2012; 224: 372-376
    Article in Thieme ConnectPubMedGoogle Scholar
  • 59 Riehm H, Gadner H, Henze G et al. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol 1980; 2: 299-306
    PubMedGoogle Scholar
  • 60 Rubnitz JE, Inaba H, Dahl G et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010; 11: 543-552
    CrossrefPubMedGoogle Scholar
  • 61 Sander A, Zimmermann M, Dworzak M et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia 2010; 24: 1422-1428
    CrossrefPubMedGoogle Scholar
  • 62 Sievers EL, Larson RA, Stadtmauer EA et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254
    PubMedGoogle Scholar
  • 63 Smith LA, Cornelius VR, Plummer CJ et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer 2010; 10: 337-351
    CrossrefPubMedGoogle Scholar
  • 64 Stevens RF, Hann IM, Wheatley K et al. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council’s 10th AML trial. MRC Childhood Leukaemia Working Party. Br J Haematol 1998; 101: 130-140
    CrossrefPubMedGoogle Scholar
  • 65 Swerdlow SH, Campo E, Harris NL et al. WHO Classification of Tumors of Haemtopoetic and Lymphoid Tissues. 4th, Lyon, France 2008
    PubMedGoogle Scholar
  • 66 Testi AM, Biondi A, Lo CF et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood 2005; 106: 447-453
    CrossrefPubMedGoogle Scholar
  • 67 Tsukimoto I, Tawa A, Horibe K et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009; 27: 4007-4013
    CrossrefPubMedGoogle Scholar
  • 68 van Dalen EC, van der Pal HJ, Caron HN et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2009; CD005008
    PubMedGoogle Scholar
  • 69 Vardiman JW, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951
    CrossrefPubMedGoogle Scholar
  • 70 Wechsler J, Greene M, McDevitt MA et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32: 148-152
    CrossrefPubMedGoogle Scholar
  • 71 Weinberg OK, Seetharam M, Ren L et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood 2009; 113: 1906-1908
    CrossrefPubMedGoogle Scholar
  • 72 Woods WG, Neudorf S, Gold S et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62
    CrossrefPubMedGoogle Scholar
  • 73 Zwaan CM, Reinhardt D, Corbacioglu S et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood 2003; 101: 3868-3871
    CrossrefPubMedGoogle Scholar
  • 74 Zwaan CM, Reinhardt D, Zimmerman M et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol 2010; 148: 768-776
    CrossrefPubMedGoogle Scholar